title: Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity.
abstract: BACKGROUND
  It has been shown that fludarabine (FLU) is superior to conventional treatment in B-CLL for rate and quality of response, leading to CR even at the molecular level. In this paper we report our preliminary results with this drug in B-CLL patients.
  
  
  METHODS
  Twenty-seven B-CLL patients (16 refractory to previous therapy, 7 responsive and treated for subsequent disease reexpansion, 4 untreated with active disease) were administered FLU at a dose of 25 mg/sqm for 5 days every 4 weeks.
  
  
  RESULTS
  Twenty-five patients were evaluable and 14 of them (56%) were responsive. All four untreated patients responded: 1 CR (PCR analysis showed the persistence of clonal VDJ rearrangement) and 3 PR, while 67% of the previously responsive group again showed a reaction: 2 PR (33%) and 2 nodular PR (33%). Among the refractory patients we recorded 6 responses (39%): 1 CR (6%) and 5 PR (33%). Besides 2 cases of lethal myelotoxicity, we observed 2 cases of encephalopathy and 2 cases of heart failure. Four deaths may have been related to FLU therapy (15%).
  
  
  CONCLUSIONS
  We confirm the effectiveness of FLU and the improved outcome, in terms of toxicity and response rate, it provides in untreated B-CLL patients. Further studies are needed to explore the possible negative effects of FLU on neuronal and heart function, and the impact of this drug on survival in selected groups of patients.
authors.affiliation: I Division of Hematology, S. Martino Hospital, Genoa.
authors.forename: M
authors.initials: M
authors.lastname: Spriano
authors.forename: M
authors.initials: M
authors.lastname: Clavio
authors.forename: P
authors.initials: P
authors.lastname: Carrara
authors.forename: L
authors.initials: L
authors.lastname: Canepa
authors.forename: M
authors.initials: M
authors.lastname: Miglino
authors.forename: I
authors.initials: I
authors.lastname: Pierri
authors.forename: L
authors.initials: L
authors.lastname: Celesti
authors.forename: E
authors.initials: E
authors.lastname: Rossi
authors.forename: R
authors.initials: R
authors.lastname: Vimercati
authors.forename: R
authors.initials: R
authors.lastname: Bruni
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine